Clinical trials: Eye Allergies
Allergic Rhinitis Due to Cat Allergy
A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat
The primary objective of the study is to determine the efficacy of REGN1908-1909, as compared to placebo, to reduce allergic rhinitis/conjunctivitis symptoms and allergy rescue medication use during natural cat exposure.
- Trial name
- NCT04981717
- Testing
- REGN1908-1909
- Where
- 92 sites in United States, Belgium and 4 more
- Volunteers
- 446 people
- Sponsor
- Regeneron Pharmaceuticals
Allergic Rhinoconjunctivitis
A Research Study in Chinese People With Allergy to House Dust Mites, Using an Environmental Exposure Chamber
This trial evaluates the efficacy and safety of HDM SLIT-tablet in treatment of HDM AR. The efficacy is evaluated using an environmental exposure chamber (EEC).
- Trial name
- QUEST (NCT04176185)
- Testing
- Sublingual allergy immunological tablet
- Where
- 2 sites in Austria, China
- Volunteers
- 80 people
- Sponsor
- ALK-Abelló A/S
Atopic Conjunctivitis
Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis
This study evaluates the efficacy and safety of Cyclosporine 0.010% eye drops in the treatment of Atopic Keratoconjunctivitis (chronic and severe inflammation of the eye).
- Trial name
- NCT00884585
- Testing
- Cyclosporine Vehicle, Cyclosporine 0.010%
- Where
- 12 sites in United States, Australia and 10 more
- Volunteers
- 176 people
- Sponsor
- Allergan
Optic Neuritis
Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
The goal of this clinical trial is to evaluate the safety and efficacy of privosegtor, a neuroprotective candidate, in patients diagnosed with optic neuritis (ON).
- Trial name
- PIONEER-1 (NCT07623668)
- Testing
- Privosegtor, Methylprednisolone
- Where
- 4 sites in United States
- Volunteers
- 210 people
- Sponsor
- Oculis
Allergic Conjunctivitis
Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis
The purpose of this study is to determine the efficacy and safety of the administration of cyclosporine and prednisolone acetate compared to placebo in the treatment of allergic conjunctivitis.
- Trial name
- NCT01120132
- Testing
- CsA high dose, CsA low dose, PA
- Where
- United States
- Volunteers
- 716 people
- Sponsor
- Fovea Pharmaceuticals SA
Allergic Conjunctivitis
Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis
In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 66 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered…
- Trial name
- NCT06686472
- Testing
- TL-925
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Telios Pharma, Inc.
Eye Manifestations
Comparison of Ectoin® Containing Eye Drops and Ectoin® Containing Eye Spray With the Eye Spray Tears Again®
This study aims to gain knowledge on the duration of symptom relief of environmental disorders of the eye as might be present in allergy sufferers after allergen exposure following application of the study products.
- Trial name
- NCT04021225
- Testing
- Ectoin® Allergy Eye Drops 2%, Ectoin® Eye Spray Colloidal, Tears Again® eye spray
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Bitop AG
Allergic Conjunctivitis
A Study Of TL-925 For The Treatment of AC
In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 70 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered…
- Trial name
- NCT06293820
- Testing
- TL-925
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Telios Pharma, Inc.
Allergic Conjunctivitis
An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis
The objective of this study is to assess safety and efficacy of long-term use of AL-4943A (Olopatadine Hydrochloride Ophthalmic Solution, 0.2%) in patients with allergic conjunctivitis.
- Trial name
- NCT01037179
- Testing
- Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
- Where
- Japan
- Volunteers
- 110 people
- Sponsor
- Alcon Research
Type 2 Inflammatory Disorders
Compassionate Use or Expanded Access of Dupilumab
Provide Compassionate Use or Expanded Access of Dupilumab
- Trial name
- NCT04776694
- Testing
- Dupilumab
- Sponsor
- Regeneron Pharmaceuticals